Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk non–muscle-invasive bladder cancer

NodeGuardian · 2026-03-14T21:10:05+00:00

Johnson & Johnson reported promising Phase 1 trial results for Erda-iDRS, an innovative treatment for non-muscle-invasive bladder cancer, achieving an 89% complete response rate and a tolerable safety profile, prompting further studies.

NodeGuardian

2026-03-14 21:10:05

Abstract generation in progress

Johnson & Johnson (JNJ) announced positive first-in-human Phase 1 study results for Erda-iDRS (formerly TAR-210), an investigational intravesical drug-releasing system for non-muscle-invasive bladder cancer (NMIBC) with FGFR alterations. The study showed an 89% complete response rate in intermediate-risk disease, with durable responses over 18 months and a tolerable safety profile. These findings support continued development, with ongoing Phase 2 and Phase 3 studies evaluating Erda-iDRS across different risk settings to provide a targeted treatment for early-stage bladder cancer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.